NASDAQ:FGEN - FibroGen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $29.50
  • Forecasted Upside: 172.90 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.81
▲ +0.01 (0.09%)

This chart shows the closing price for FGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New FibroGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FGEN

Analyst Price Target is $29.50
▲ +172.90% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $29.50, with a high forecast of $58.00 and a low forecast of $11.00. The average price target represents a 172.90% upside from the last price of $10.81.

This chart shows the closing price for FGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in FibroGen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$16.00 ➝ $11.00High
8/20/2021Raymond JamesUpgradeUnderperform ➝ Market PerformMedium
8/11/2021The Goldman Sachs GroupBoost Price TargetNeutral$16.00 ➝ $22.00Low
8/10/2021SVB LeerinkLower Price TargetPositive ➝ Outperform$35.00 ➝ $30.00Low
7/16/2021SVB LeerinkReiterated RatingOutperform$56.00 ➝ $35.00High
7/16/2021CowenLower Price TargetMarket Perform$21.00 ➝ $16.00High
7/16/2021MizuhoLower Price TargetNeutral$32.00 ➝ $18.00High
7/16/2021Bank of AmericaDowngradeBuy ➝ Neutral$29.00High
7/16/2021Stifel NicolausDowngradeBuy ➝ Hold$55.00 ➝ $29.00High
6/28/2021MizuhoBoost Price TargetPositive ➝ Neutral$29.00 ➝ $32.00Low
4/13/2021HC WainwrightReiterated RatingBuy ➝ NeutralN/A
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$29.00N/A
4/7/2021JPMorgan Chase & Co.UpgradeNeutralHigh
4/7/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $56.00High
4/7/2021Raymond JamesReiterated RatingSellHigh
4/7/2021MizuhoDowngradeBuy ➝ Neutral$72.00 ➝ $29.00High
4/7/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
3/31/2021Bank of AmericaUpgradeNeutral ➝ Buy$47.00High
3/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$75.00 ➝ $45.00N/A
3/2/2021SVB LeerinkLower Price TargetOutperform$91.00 ➝ $64.00High
3/2/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$75.00 ➝ $45.00High
2/1/2021HC WainwrightInitiated CoverageBuy$58.00Low
11/6/2020SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $92.00Low
10/26/2020Raymond JamesInitiated CoverageUnderperformHigh
9/8/2020SVB LeerinkBoost Price TargetOutperform$84.00 ➝ $90.00Low
8/7/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $84.00High
5/11/2020MizuhoReiterated RatingBuyHigh
5/8/2020SVB LeerinkLower Price TargetOutperform$85.00 ➝ $80.00Low
5/1/2020CowenInitiated CoverageMarket Perform$40.00High
4/27/2020Bank of AmericaInitiated CoverageNeutral$45.00Low
4/20/2020MizuhoReiterated RatingBuy$72.00High
3/19/2020CitigroupLower Price TargetBuy$65.00 ➝ $51.00High
2/13/2020MizuhoReiterated RatingBuy$72.00High
11/18/2019MizuhoReiterated RatingBuy$72.00Low
11/11/2019MizuhoReiterated RatingBuy ➝ Positive$65.00 ➝ $72.00High
8/26/2019MizuhoReiterated RatingBuy$65.00Medium
8/11/2019MizuhoReiterated RatingBuy$65.00High
7/2/2019William BlairReiterated RatingHoldLow
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$45.00Low
5/27/2019Piper Jaffray CompaniesReiterated RatingNeutral ➝ Positive$65.00 ➝ $40.00Low
5/10/2019William BlairDowngradeOutperform ➝ Market PerformHigh
5/10/2019MizuhoLower Price TargetBuy ➝ Positive$74.00 ➝ $65.00High
4/12/2019Piper Jaffray CompaniesInitiated CoverageNeutral$65.00High
2/11/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$71.00High
12/18/2018CitigroupUpgradeNeutral ➝ Buy$71.00Medium
12/17/2018MizuhoReiterated RatingBuy$74.00Medium
10/15/2018SVB LeerinkSet Price TargetOutperform ➝ Buy$82.00 ➝ $84.00Low
9/11/2018SVB LeerinkSet Price TargetBuy$82.00Low
8/8/2018CitigroupDowngradeBuy ➝ Hold$71.00High
8/8/2018MizuhoReiterated RatingBuy$74.00High
6/19/2018MizuhoReiterated RatingPositive ➝ Buy$74.00High
6/1/2018MizuhoReiterated RatingBuy$61.00Low
5/15/2018MizuhoUpgradeNeutral ➝ Buy$61.00High
3/29/2018MizuhoReiterated RatingHold$61.00Low
2/28/2018SVB LeerinkReiterated RatingOutperform$80.00 ➝ $88.00High
11/9/2017MizuhoReiterated RatingHold$61.00N/A
10/4/2017MizuhoInitiated CoverageNeutral$61.00N/A
9/14/2017Stifel NicolausReiterated RatingBuy$80.00Low
9/12/2017Jefferies Financial GroupReiterated RatingBuy$75.00Low
8/9/2017William BlairReiterated RatingOutperformMedium
8/8/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$52.00 ➝ $82.00High
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 ➝ $65.00High
8/8/2017Jefferies Financial GroupReiterated RatingPositive ➝ Buy$75.00 ➝ $75.00High
8/8/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$38.00 ➝ $80.00High
7/21/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral$31.00Medium
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$50.00High
6/26/2017CitigroupReiterated RatingBuy$48.00High
6/26/2017William BlairReiterated RatingOutperformMedium
6/22/2017Stifel NicolausReiterated RatingBuy$32.00 ➝ $38.00Low
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/A
1/18/2017Stifel NicolausReiterated RatingPositive$33.00N/A
11/9/2016SVB LeerinkReiterated RatingBuy$52.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 3 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
7/29/2021
  • 10 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
FibroGen logo
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $10.81
Low: $10.62
High: $10.95

50 Day Range

MA: $12.31
Low: $10.18
High: $14.41

52 Week Range

Now: $10.81
Low: $9.89
High: $57.21

Volume

948,467 shs

Average Volume

1,378,758 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of FibroGen?

The following Wall Street analysts have issued research reports on FibroGen in the last year: Bank of America Co., Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Raymond James, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for FGEN.

What is the current price target for FibroGen?

8 Wall Street analysts have set twelve-month price targets for FibroGen in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 173.1%. HC Wainwright has the highest price target set, predicting FGEN will reach $58.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for FibroGen in the next year.
View the latest price targets for FGEN.

What is the current consensus analyst rating for FibroGen?

FibroGen currently has 1 sell rating, 8 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FGEN, but not buy more shares or sell existing shares.
View the latest ratings for FGEN.

How do I contact FibroGen's investor relations team?

FibroGen's physical mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 978-1200 and its investor relations email address is [email protected] The official website for FibroGen is www.fibrogen.com.